IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31

IRONWOOD PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.56+0.06 (+1.71%)

Close on Oct 19, 2026

Market cap: $595.16M
P/E (TTM): 4.6
Dividend yield: –

IRONWOOD PHARMACEUTICALS INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	296	351	443	411	414	390	428	347	298	274	150	76	23	150	66	44	34
Cost of Revenue	–	–	–	–	–	3.14	24	33	19	1.87	0.01	5.29	7.20	0.97	–	–	–
Gross Profit	–	–	–	–	–	386	405	314	279	272	150	71	16	149	–	–	–
Research & Development	95	111	116	44	70	88	115	101	88	139	109	102	102	113	86	77	76
Selling, General & Admin	82	144	158	116	111	140	172	220	231	173	125	118	123	93	46	27	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	46	27	19
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	132	105	95
Total Costs & Expenses	198	258	1,388	160	181	247	308	497	314	326	252	246	275	223	132	105	–
Operating Income	99	93	-945	250	232	143	120	-151	-15	-52	-102	-169	-252	-73	-66	-61	-61
Interest Expense	33	33	22	7.60	31	29	37	38	36	39	31	21	21	0.06	0.06	0.20	0.32
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	0.20	0.46	0.61	0.24
Other Non-Operating Income	-28	-28	-2.64	2.09	-32	-34	-61	-43	-40	-30	-41	-20	-21	0.14	1.29	1.41	0.52
Merger & Restructuring Charges	21	2.61	17	–	1.07	15	3.60	15	–	–	–	0.55	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	0	0	0	0	0	0	0	0	0	–	–	0.90
Gain (Loss) on Sale of Assets	-0.09	-0.08	–	0.00	-0.09	-0.47	-0.15	1.87	-0.69	0.20	0.20	-0.12	-0.61	-0.02	-0.01	-0.47	-0.08
Pretax Income	70	65	-948	252	201	109	59	-194	–	–	–	–	-273	-73	-65	-59	-60
Income Tax Expense	46	64	83	77	-328	2.69	0	0	0	0	0	0	–	–	0.00	-2.94	-0.30
Income from Continuing Operations	–	–	–	–	528	106	59	-194	-55	–	–	–	–	-73	-65	-56	-60
Income from Discontinued Operations	–	–	–	–	–	–	-37	-88	-62	–	–	–	–	–	–	4.55	-13
Net Income incl. Noncontrolling Interests	24	0.88	-1,032	175	528	106	22	-282	-117	-82	-143	–	–	-73	-65	-52	-73
Minority Interest in Earnings	–	–	-29	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	24	0.88	-1,002	175	528	106	22	-282	-117	-82	-143	–	–	–	–	–	–
Net Income to Common	24	0.88	-1,002	175	528	106	22	-282	–	-82	-143	-190	-273	-73	-65	-53	-71
EPS (Basic)(per share)	0.15	0.01	-6.45	1.13	3.26	0.67	0.14	-1.85	-0.78	-0.56	-1.00	-1.39	-2.35	-0.68	-0.65	-0.59	-10.00
EPS (Diluted)(per share)	0.15	0.01	-6.45	0.96	3.21	0.66	0.14	-1.85	-0.78	-0.56	-1.00	-1.39	-2.35	-0.68	-0.65	-0.59	-10.00
Shares Outstanding (Basic, Weighted)(shares)	162	159	155	154	162	159	156	153	149	145	142	137	116	106	100	90	7.12
Shares Outstanding (Diluted, Weighted)(shares)	163	160	155	186	164	161	156	153	149	145	142	137	116	106	100	90	7.12
EBITDA	100	94	-944	252	234	145	126	-147	-8.96	-42	-90	-157	-240	-61	-56	-55	-56

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 60.1%
Net margin: 33.4%
Return on equity, FY2025: -8.5%

Financial strength

Current ratio: 6.06
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 240.8%

Valuation

P/E ratio: 4.6
Price to sales: 1.53
Price to book: –
Dividend yield: –